HLS Therapeutics Inc.
TSX:HLS.TODrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $116.32M
- Beta
- 0.85
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.33
Volume 0.04M
Average 0.01M
HLS.TO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
HLS Therapeutics Inc.TSX: HLS.TO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $142K fell 78.2% year over year, behind the -30.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 1190.9% from the prior quarter. Over 3 fiscal years it compounded at -13.2% a year.
Context
- Stock-based compensation amounted to 3.4% of revenue in FY2025, up 0.5 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -78.2% toward the trailing-twelve-month pace of -30.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.91M USD
- Year-over-year change
- +18.2%
- 4-year CAGR
- -5.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.91M | +18.2% |
| FY2024 | 2024-12-31 | 1.62M | +400.6% |
| FY2023 | 2023-12-31 | (538K) | -118.4% |
| FY2022 | 2022-12-31 | 2.92M | +24.1% |
| FY2021 | 2021-12-31 | 2.35M | — |
Stock-Based Compensation vs competitors
How HLS.TO compares with its peers on the latest reported figures
- HLS.TO's LTM Mar 2026 stock-based compensation of $1.4M is the 6th largest of the 7 companies compared; the peer median is $17.58M.
- Its year-over-year change of -30.3% is the lowest of 6, against a peer median of +17.6%.
- Stock-based compensation amounts to 2.5% of revenue for HLS.TO, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $10.98B | — | +586.2% | — | |
| LTM Jun 2026 | $149M | +12.9% | +19.7% | 1.4% | |
| LTM Jun 2026 | $26.81M | -10.2% | +0.1% | 0.9% | |
| LTM Mar 2026 | $8.36M | +17.6% | +20.3% | 16.6% | |
| LTM Mar 2026 | $5.83M | +64.5% | +9.3% | 6.7% | |
| LTM Mar 2026 | $1.4M | -30.3% | -13.2% | 2.5% | |
| LTM Mar 2026 | $440.95K | +48.3% | -3.0% | 1.1% | |
| Peer median (excluding HLS.TO) | $17.58M | +17.6% | +14.5% | 1.4% | |
Competitors are the stored peer set for HLS.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.12M) | (23.6M) | (27.53M) | (19.66M) | (12.43M) |
| Depreciation & Amortization | 30.26M | 34.4M | 31.94M | 22.72M | 22.2M |
| Deferred Income Tax | 1.14M | 138K | (696K) | 3.81M | (1.3M) |
| Stock-Based Compensation | 2.35M | 2.92M | (538K) | 1.62M | 1.91M |
| Change in Working Capital | (3.02M) | 1.55M | 5.04M | 1.14M | 4.82M |
| Accounts Receivables | 1.04M | (71K) | 629K | 2.37M | 1.02K |
| Inventory | 1.77M | (622K) | (661K) | (189K) | 1.3M |
| Accounts Payables | (3.65M) | 3.24M | 1.99M | (4.3M) | 857.76K |
| Other Working Capital | (2.19M) | (999K) | 3.08M | 3.26M | 2.66M |
| Other Non-Cash Items | (1.19M) | 1.53M | 7.58M | (1.63M) | 819.78K |
| Operating Cash Flow | 16.43M | 16.94M | 15.79M | 8M | 16.02M |
| Capital Expenditures | (4.51M) | (10.15M) | (189K) | (15K) | (208.59K) |
| Acquisitions (Net) | 0 | 0 | 0 | (1.5M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (4.46M) | (10.1M) | (148K) | 13.25M | 0 |
| Investing Cash Flow | (4.51M) | (10.15M) | (189K) | 11.74M | (1.73M) |
| Debt Repayment | (11.14M) | (441K) | (9.46M) | (21.57M) | (18.07M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (47K) | (998K) | (1.55M) | (600K) | (1.83M) |
| Dividends Paid | (5.12M) | (4.96M) | (2.4M) | 0 | 0 |
| Other Financing Activities | 4.91M | (455K) | (1.23M) | (1.19M) | (624.75K) |
| Financing Cash Flow | (11.4M) | (6.86M) | (14.64M) | (23.36M) | (20.52M) |
| Effect of Forex Changes | 46K | (394K) | 268K | (870K) | (343.66K) |
| Net Change in Cash | 567K | (456K) | 1.23M | (4.5M) | (6.58M) |
| Free Cash Flow | 11.92M | 6.79M | 15.6M | 7.99M | 15.81M |
HLS Therapeutics Inc.
TSX:HLS.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.